Tumorigenesis Inhibition of Carnosol From Rosemary: an Insight to Molecular Targeting

Document Type : Original paper


1 Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

2 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Department of Traditional Medicine, School of Traditional Medicine Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Research Institute for Gastroenterology and Liver Diseases, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Background and objectives: Anti-proliferative activity of carnosol from Rosemary on malignancies has revealed its potential for cancer therapeutic purposes. Molecular studies such as proteomics could open a new insight in underling mechanisms of anticancer processes of carnosol treatment through analysis of the most relevant modulated proteins in cancer. Methods: Protein-protein interaction (PPI) network analysis of adult T-cell leukemia/lymphoma (ATL) treated with carnosol proteome was conducted. Cyroscape and its plug-ins explored the PPI network construction and its features including centrality and gene ontology. Results: Among 22 differentially expressed proteins (DEPs), 21 individuals were recognized by the STRING database. The queried DEPs and the added first neighbors formed a scale-free network. GAPDH, TPI1, ENO1, and PGK1 were identified as the hub-bottlenecks of the PPI network of carnosol-treated ATL. Conclusion: ALDOA, PFKFB3, PKM2, and LDHA and related metabolic processes are targets of anticancer compounds of rosemary extract; however, more investigation is suggested.


  • Fernández-Ochoa Á, Borrás-Linares I, Pérez-Sánchez A, Barrajón-Catalán E, González-Álvarez I, Arráez-Román D, Micol V, Segura-Carretero Phenolic compounds in rosemary as potential source of bioactive compounds against colorectal cancer: in situ absorption and metabolism study. J Funct Foods. 2017; 33: 202–210.
  • González-Vallinas M, Molina S, Vicente G, Zarza V, Martín-Hernández R, Garcia-Risco M, Fornari T, Reglero G, de Molina Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of rosemary diterpenes in colon and pancreatic cancer. PLoS One. 2014; 9(6): 1–10.
  • Valdes A, Artemenko KA, Bergquist J, Garcia-Canas V, Cifuentes A. Comprehensive proteomic study of the antiproliferative activity of a polyphenol-enriched rosemary extract on colon cancer cells using nanoliquid chromatography–orbitrap MS/MS. J Proteome Res. 2016; 15(6): 1971–1985.
  • Ishida YI, Yamasaki M, Yukizaki C, Nishiyama K, Tsubouchi H, Okayama A, Kataoka Carnosol, rosemary ingredient, induces apoptosis in adult T-cell leukemia/lymphoma cells via glutathione depletion: proteomic approach using fluorescent two-dimensional differential gel electrophoresis. Hum Cell. 2014; 27(2): 68–77.
  • Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, Georgiadis C, Laskin JD, Conney Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res. 1994; 54(3): 701–708.
  • Jang YG, Hwang KA, Choi KC. Rosmarinic acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines. Nutrients. 2018; 10(11): 1–15.
  • González-Vallinas M, Reglero G, Ramírez de Molina A. Rosemary (Rosmarinus officinalis) extract as a potential complementary agent in anticancer therapy. Nutr Cancer. 2015; 67(8): 1223–1231.
  • Valdés A, García-Cañas V, Pérez-Sánchez A, Barrajón-Catalán E, Ruiz-Torres V, Artemenko KA, Micol V, Bergquist J, Cifuentes Shotgun proteomic analysis to study the decrease of xenograft tumor growth after rosemary extract treatment. J Chromatogr A. 2017; 26(1499): 90–100.
  • Aruoma O, Halliwell B, Aeschbach R, Löligers J. Antioxidant and pro-oxidant properties of active rosemary constituents: carnosol and carnosic acid. Xenobiotica. 1992; 22(2): 257–268.
  • Valdés A, García-Cañas V, Artemenko KA, Simó C, Bergquist J, Cifuentes A. Nano-liquid chromatography-orbitrap MS-based quantitative proteomics reveals differences between the mechanisms of action of carnosic acid and carnosol in colon cancer cells. Mol Cell Proteomics. 2017; 16(1): 8–22.
  • Nosaka K, Matsuoka M. Adult T‐cell leukemia‐lymphoma as a viral disease: subtypes based on viral aspects. Cancer Sci. 2021; 112(5): 1688–1694.
  • Jiao R, Liu Y, Gao H, Xiao J, So KF. The anti-oxidant and antitumor properties of plant polysaccharides. Am J Chin Med. 2016; 44(03): 463–488.
  • Azodi MZ, Tavirani MR, Tavirani MR, Nejad MR. Bioinformatics investigation and contribution of other chromosomes besides chromosome 21 in the risk of down syndrome development. Basic Clin Neurosci. 2021; 12(1): 79–88.
  • Rezaei-Tavirani M, Rezaei-Tavirani S, Mansouri V, Rostami-Nejad M, Rezaei-Tavirani M. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. Asian Pac J Cancer Prev. 2017; 18(12): 3357–3363.
  • Rezaei-Tavirani M, Rezaei-Tavirani S, Ahmadi N, Naderi N, Abdi S. Pancreatic adenocarcinoma protein-protein interaction network analysis. Gastroenterol Hepatol Bed Bench. 2017; 10(S1): 85–92.
  • Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(1): 362–368.
  • Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Sys Biol. 2014; 8(4): 1–7.
  • Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. 2008; 24(2): 282–284.
  • Morris JH, Kuchinsky A, Ferrin TE, Pico AR. Enhancedgraphics: a cytoscape app for enhanced node graphics. F1000 Res. 2014; 3(147): 1–8.
  • Zhang JY, Zhang F, Hong CQ, Giuliano AE, Cui XJ, Zhou GJ, Zhang GJ, Cui Critical protein GAPDH and its regulatory mechanisms in cancer cells. Cancer Biol Med. 2015; 12(1): 10–22.
  • Mondragón L, Mhaidly R, De Donatis GM, Tosolini M, Dao P, Martin AR, Pons C, Chiche J, Jacquin M, Imbert V, Proïcs E, Boyer L, Doye A, Luciano F, Neels JG, Coutant F, Fabien N, Sormani L, Rubio-Patiño C, Bossowski JP, Muller F, Marchetti S, Villa E, Peyron JF, Gaulard P, Lemonnier F, Asnafi V, Genestier L, Benhida R, Fournié JJ, Passeron T, Ricci JE, Verhoeyen GAPDH overexpression in the T cell lineage promotes angioimmunoblastic T cell lymphoma through an NF-κB-dependent mechanism. Cancer Cell. 2019; 36(3): 268–287.
  • Ishii T, Mori T, Tanaka T, Mizuno D, Yamaji R, Kumazawa S, Nakayama T, Akagawa Covalent modification of proteins by green tea polyphenol (–)-epigallocatechin-3-gallate through autoxidation. Free Radic Biol Med. 2008; 45(10): 1384–1394.
  • Yu WL, Yu G, Dong H, Chen K, Xie J, Yu H, Ji Y, Yang GS, Li AJ, Cong WM, Jin Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma. J Gastroenterol. 2020; 55(12): 1171–1182.
  • Xiao H, Zhang Y, Kim Y, Kim S, Kim JJ, Kim KM, Yoshizawa J, Fan LY, Cao CX, Wong Differential proteomic analysis of human saliva using tandem mass tags quantification for gastric cancer detection. Sci Rep. 2016; 6(1): 1–13.
  • Chen T, Huang Z, Tian Y, Lin B, He R, Wang H, Ouyang P, Chen H, Wu Clinical significance and prognostic value of triosephosphate isomerase expression in gastric cancer. Medicine. 2017; 96(19): 1–6.
  • Wang G, Wang YZ, Yu Y, Wang JJ, Yin PH, Xu K. Triterpenoids extracted from Rhus chinensis Mill act against colorectal cancer by inhibiting enzymes in glycolysis and glutaminolysis: network analysis and experimental validation. Nutr Cancer. 2020; 72(2): 293–319.
  • Cao H, Yu H, Feng Y, Chen L, Liang F. Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis. Cancer Chemother Pharmacol. 2017; 79(5): 985–994.
  • He Y, Luo Y, Zhang D, Wang X, Zhang P, Li H, Ejaz S, Liang PGK1-mediated cancer progression and drug resistance. Am J Cancer Res. 2019; 9(11): 2280–2302.